Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says

Galderma said rising GLP-1 use is driving strong demand for aesthetics treatments tied to “Ozempic face,” with CEO Flemming Ørnskov calling it a “significant opportunity, but it’s still early days.” The company reported nearly 25% sales growth at constant currencies year-on-year, with U.S. growth outpacing the rest at 32% vs 19% outside the U.S. The stock was little moved in mid-morning trading, suggesting more fundamental momentum than immediate market repricing.

Analysis

This is less a one-time product story than a distribution tailwind for cash-pay aesthetics. The key mechanism is not just more consultations, but a higher conversion rate into mid-ticket injectables and repeat maintenance procedures, which can lift revenue per patient without requiring a huge change in procedure volume. That favors diversified aesthetic franchises with broad salesforce reach and multiple SKUs; it is less helpful for single-procedure names that need one hero product to drive the thesis.

The first-order beneficiaries are the large aesthetic incumbents and the med-spa channel, while the second-order winners are suppliers of consumables, practice-management software, and training platforms that monetize more patient traffic. The market may be underestimating how much of this demand is a channel effect: once providers start routinely mentioning post-weight-loss facial volume loss, the category can become self-reinforcing through peer adoption and social media, but that effect usually takes 2-4 quarters to show up in reported numbers.

The contrarian risk is that the current narrative overstates incremental TAM. Some of the spend is likely cannibalized from existing cosmetic budgets rather than newly created, and discretionary aesthetics is still exposed to consumer downturns and price sensitivity. What would falsify the thesis is a lack of follow-through in U.S. aesthetics growth over the next two earnings cycles, or evidence that GLP-1 users are not converting into repeat procedure spend. In that case, this remains a good marketing story but a weak P&L driver.

Key Decisions for Investors

• Watchlist, not immediate trade: wait for the next 1-2 earnings prints from ABBV and EOLS for explicit GLP-1-related commentary. If U.S. aesthetics growth stays >low-teens without incremental promo spend, the signal is real; if not, avoid paying up for the theme.
• Relative-value idea: long ABBV / short EOLS over 3-6 months. ABBV has the broader portfolio to monetize a rising patient funnel across toxin, filler, and repeat treatments; EOLS is more dependent on procedure-level share gains. Falsify if EOLS posts materially faster U.S. sell-through or share gains.
• If you want a cleaner expression of the channel effect, consider a basket long of ABBV plus a small position in consumer-discretionary med-spa beneficiaries versus the S&P 500, sized modestly because the thesis needs hard evidence from channel checks.
• Do not chase the story in the underlying after a single strong quarter. Best entry is on any post-earnings pullback if management confirms that GLP-1-linked demand is recurring; if not confirmed, treat it as a narrative trade with limited duration.